THE GLUTATHIONE DECISION

Which Strategy Actually Moves the Needle on Your Master Antioxidant?

 By the Bio Precision Editorial Team - April 2026

The Science Spotlight

Why Glutathione Matters More Than You Think

 Glutathione (GSH) is a tripeptide composed of three amino acids — cysteine, glycine, and glutamic acid — and it is the most abundant intracellular antioxidant in the human body. Found in virtually every cell at millimolar concentrations, it serves as the linchpin of your entire antioxidant defense system. Researchers and clinicians frequently refer to it as the “master antioxidant” for good reason: it doesn’t just neutralize free radicals on its own, it regenerates other critical antioxidants like vitamins C and E, recycling them back into their active forms.

Glutathione exists in two states within cells: the reduced, active form (GSH) and the oxidized, inactive form (GSSG). In healthy cells, reduced GSH accounts for more than 98% of total glutathione. The ratio of GSH to GSSG is one of the most reliable biomarkers of cellular redox status and, by extension, cellular health. When that ratio shifts toward GSSG, it signals oxidative stress, impaired detoxification, and accelerated aging.

Here is the challenge that makes this article necessary: glutathione levels decline significantly with age. The body’s capacity to synthesize GSH diminishes as we get older, and the demand for it simultaneously increases due to cumulative environmental toxin exposure, chronic inflammation, metabolic stress, and mitochondrial dysfunction. Research from Baylor College of Medicine has demonstrated that older adults show severe GSH depletion compared to younger adults, with reduced-to-oxidized glutathione ratios falling from approximately 10:1 in young subjects to near 1:1 in older adults.

This presents a practical question for anyone pursuing longevity and peak performance: what is the most effective way to restore and maintain optimal glutathione levels? The three most widely used strategies are oral N-acetylcysteine (NAC), oral glutathione supplementation, and injectable (intravenous or intramuscular) glutathione. Each approach has distinct pharmacokinetic properties, clinical evidence, advantages, and limitations.

Clinical Context: The GSH Depletion Cascade

Glutathione deficiency doesn’t operate in isolation. Research has linked declining GSH levels to a cascade of age-associated dysfunctions including mitochondrial impairment, elevated oxidative stress, chronic low-grade inflammation, insulin resistance, endothelial dysfunction, cognitive decline, and sarcopenia. Restoring glutathione is not merely an antioxidant strategy — it is a systems-level intervention.

Precision in Practice

The Three Contenders: Mechanism, Bioavailability, and Evidence

Strategy 1: Oral N-Acetylcysteine (NAC)

Mechanism of Action

NAC is not glutathione. It is a precursor — a stabilized form of the amino acid L-cysteine, which is the rate-limiting substrate in glutathione biosynthesis. When you take NAC orally, your body absorbs it through the gastrointestinal tract, deacetylates it to release free cysteine, and then your cells combine that cysteine with glycine and glutamic acid via the enzymes glutamate-cysteine ligase (GCL) and glutathione synthetase (GSS) to produce endogenous glutathione.

This is an important distinction: NAC supports your body’s natural glutathione production rather than supplying preformed GSH directly. The advantage is that intracellular GSH synthesis is self-regulating — your cells produce glutathione in proportion to demand, avoiding the theoretical risk of “reductive stress” from supraphysiological GSH concentrations.

Bioavailability

Oral NAC has well-characterized oral bioavailability, estimated at approximately 6–10% due to significant first-pass hepatic metabolism. However, this figure is somewhat misleading in context because NAC’s therapeutic value does not depend on NAC itself reaching tissues intact — it depends on the cysteine it delivers reaching cells and being incorporated into glutathione synthesis. Studies consistently demonstrate that oral NAC supplementation at 600–1,200 mg per day reliably increases intracellular glutathione levels over days to weeks of consistent use.

What the Research Shows

NAC has one of the most extensive clinical track records of any supplement relevant to glutathione metabolism. It has FDA approval as a mucolytic agent and as the antidote for acetaminophen toxicity, where it works by replenishing hepatic glutathione stores.

For general antioxidant support, a randomized crossover trial published in Redox Biology (2015) compared NAC, oral glutathione, and sublingual glutathione in 20 subjects with metabolic syndrome over three weeks per intervention. NAC produced significant improvements in glutathione levels and oxidative stress markers, performing substantially better than standard oral glutathione, though slightly behind sublingual GSH for direct plasma GSH elevation.

NAC also has demonstrated benefits beyond glutathione precursor activity. Clinical studies have shown reductions in inflammatory markers such as high-sensitivity C-reactive protein (hs-CRP) and improvements in respiratory function. NAC can also act as a direct antioxidant by scavenging certain reactive oxygen species independently of its role in glutathione synthesis.

Practical Considerations

•       Typical dosing: 600–1,200 mg daily, often split into two doses

•       Well-tolerated; most common side effects are mild GI symptoms (nausea, bloating)

•       Generally affordable at $0.10–$0.40 per day

•       Can be taken indefinitely as a daily supplement

•       Interactions: may interact with nitroglycerin, some blood thinners, and certain chemotherapy agents

Precision Note: NAC’s effectiveness as a glutathione precursor depends on your body’s capacity to synthesize GSH from its component amino acids. This capacity can be impaired in older adults and individuals with liver dysfunction or certain genetic polymorphisms (e.g., GST, GCLC, GCLM variants). If you are over 60 or have compromised liver function, NAC alone may not fully restore glutathione levels.

Strategy 2: Oral Glutathione

Mechanism of Action

Oral glutathione supplementation attempts to deliver preformed, reduced GSH directly through the digestive tract. The concept is straightforward: rather than relying on the body’s synthetic machinery, you supply the finished product. However, the execution encounters significant biochemical obstacles.

The Bioavailability Problem

Standard (unmodified) oral glutathione has historically been considered poorly bioavailable. The primary reason is enzymatic degradation: the gastrointestinal tract contains substantial amounts of gamma-glutamyltranspeptidase (GGT), an enzyme that breaks glutathione down into its constituent amino acids before it can be absorbed intact. Additionally, the acidic environment of the stomach can oxidize the reduced (active) form of GSH to the inactive GSSG form.

A landmark 1992 study gave subjects a single 3-gram dose of oral GSH and observed no significant increase in blood glutathione levels. A 2011 randomized, double-blind, placebo-controlled trial administering 500 mg twice daily for four weeks also found no change in total GSH, reduced GSH, oxidized GSSG, or the GSH/GSSG ratio, and no reduction in oxidative stress markers.

These results initially appeared to close the door on oral glutathione. However, subsequent research has nuanced the picture considerably.

Newer Formulations: Liposomal and Sublingual GSH

Liposomal Glutathione: Liposomal delivery encapsulates GSH within phospholipid vesicles, protecting it from enzymatic degradation and gastric oxidation. A Penn State pilot study (Sinha et al., published in the European Journal of Clinical Nutrition, 2018) demonstrated that liposomal GSH at 500–1,000 mg per day increased whole blood glutathione by up to 40%, erythrocyte GSH by 25%, plasma GSH by 28%, and peripheral blood mononuclear cell (PBMC) GSH by 100% within two weeks. These increases were accompanied by a 35% reduction in plasma 8-isoprostane (a marker of oxidative damage) and a 20% decrease in the oxidized-to-reduced glutathione ratio.

Perhaps most notably, natural killer (NK) cell cytotoxicity increased up to 400% and lymphocyte proliferation improved up to 60%, suggesting meaningful immune function enhancement.

Sublingual Glutathione: Sublingual delivery bypasses the gastrointestinal tract entirely by absorbing GSH through the oral mucosa directly into the bloodstream. A randomized crossover trial published in Redox Biology (2015) found sublingual GSH to be significantly superior to both standard oral GSH and NAC for raising plasma GSH levels and improving the GSH/GSSG ratio over a three-week period. Sublingual GSH also produced a significant increase in plasma vitamin E levels, suggesting enhanced recycling of other antioxidants.

Standard Oral GSH (Reassessed): Interestingly, a longer-duration study by Richie et al. (2015) demonstrated that standard oral GSH at 250 or 1,000 mg per day did increase body stores of glutathione over six months in a dose-dependent manner, with the 1,000 mg dose producing 30–35% increases in GSH across red blood cells, plasma, and lymphocytes. This suggests that prolonged supplementation may overcome acute bioavailability challenges through mechanisms not yet fully understood, possibly involving intestinal uptake pathways or precursor recycling.

Practical Considerations

•       Standard oral GSH: 250–1,000 mg daily; may require months for measurable effects

•       Liposomal GSH: 500–1,000 mg daily; effects visible within 1–2 weeks

•       Sublingual GSH: Doses vary; bypasses GI degradation entirely

•       Cost: Moderate to high ($1–$4 per day depending on formulation quality)

•       Generally well-tolerated; occasional mild GI discomfort

Precision Note: If you choose oral glutathione, formulation matters enormously. Standard capsules face significant absorption challenges. Liposomal preparations have the strongest evidence for raising blood and tissue GSH levels effectively. Look for products with documented particle size analysis and stability testing.

Strategy 3: Injectable Glutathione (IV, IM, and Subcutaneous)

Mechanism of Action

Injectable glutathione — whether administered intravenously (IV), intramuscularly (IM), or subcutaneously (SubQ) — delivers reduced GSH directly into the body while completely bypassing gastrointestinal degradation. Each route produces a distinct pharmacokinetic profile, and understanding these differences is critical for choosing the right injectable strategy.

Pharmacokinetics: The Spike-and-Fade Profile

The pharmacokinetic data on IV glutathione are striking and instructive. A foundational study by Aebi et al. (1991), published in the European Journal of Clinical Investigation, administered 2 g/m² of IV glutathione to healthy volunteers and observed plasma GSH concentrations surge from a baseline of approximately 17.5 μmol/L to 823 μmol/L — a roughly 47-fold increase. However, the elimination half-life was only 14.1 ± 9.2 minutes. Within 90 minutes of infusion, urinary excretion of glutathione increased 300-fold.

This means IV glutathione produces a massive but extremely transient spike in plasma GSH. The exogenous glutathione is rapidly broken down by extracellular gamma-glutamyltranspeptidase into its constituent amino acids (cysteine, glycine, glutamate), which are then taken up by cells and can be resynthesized into intracellular glutathione. In this sense, high-dose IV GSH functions partly as a very expensive cysteine delivery system.

Intramuscular (IM) injection provides a slower absorption profile, with peak plasma concentrations reached within approximately 5 hours, potentially offering a more sustained elevation compared to IV. However, IM glutathione pharmacokinetics are less well studied.

Subcutaneous (SubQ) Injection: The Home-Use Game Changer

Subcutaneous glutathione injection has emerged as a rapidly growing alternative that sits between IV and IM in terms of pharmacokinetic profile, while offering a major practical advantage: it can be self-administered at home. SubQ injection delivers glutathione into the fatty tissue beneath the skin (the hypodermis), where it is absorbed into the bloodstream through local capillary and lymphatic networks.

From a pharmacokinetic standpoint, SubQ absorption is slower than both IV and IM delivery.

Subcutaneous tissue has fewer blood vessels than muscle, which means the drug forms a local depot that releases gradually into circulation. While no published peer-reviewed pharmacokinetic study has been conducted specifically on subcutaneous glutathione, the general pharmacology of subcutaneous drug delivery is well established: absorption is slower and more sustained than IM injection, producing a lower peak concentration (Cmax) but a longer duration of exposure compared to IV.

This depot effect may actually work in glutathione’s favor. Recall that IV glutathione’s Achilles heel is its ~14-minute plasma half-life — the massive spike is cleared almost as quickly as it arrives. A subcutaneous depot theoretically extends the window during which circulating GSH and its breakdown products (particularly cysteine) are available for cellular uptake and intracellular GSH resynthesis. Instead of a single overwhelming pulse, SubQ provides a more gradual release — pharmacologically, a sustained-release profile without the engineered formulation.

Compounding pharmacies typically formulate subcutaneous glutathione at concentrations of 200 mg/mL, with common protocols prescribing 100–200 mg per injection administered every 1–3 days, or higher doses of 200–500 mg two to three times per week. The lower per-dose amounts reflect the volume limitations of subcutaneous injection (generally capped at 1–2 mL per site to avoid discomfort and ensure proper absorption) and the more frequent dosing schedule compared to IV.

SubQ vs. IV vs. IM: The Three-Route Comparison

Intravenous (IV): Highest immediate plasma concentration. Near-100% bioavailability. Ultra-short half-life (~14 minutes). Requires clinical setting, venous access, and trained personnel. Best for acute situations requiring maximum immediate GSH delivery. Highest cost per session ($150–$400+). Not sustainable for daily or even weekly long-term use for most individuals.

Intramuscular (IM): Moderate absorption speed with peak levels at approximately 5 hours. Creates a muscle depot for sustained release relative to IV. Can be administered in a clinical setting or by trained personnel. Typical doses of 200–1,000 mg per session, 1–3 times weekly. Moderate cost. Injection site soreness is occasionally reported.

Subcutaneous (SubQ): Slowest absorption of the three injectable routes, creating the longest-lasting depot effect. Lower peak plasma concentrations but more sustained exposure window. Can be self-administered at home with minimal training using insulin-type syringes. Typical doses of 100–500 mg per injection, administered every 1–3 days. Lowest per-session cost among injectables. Injection sites include abdomen, thigh, or upper arm, and should be rotated to prevent local irritation.

The SubQ Advantage for Longevity Protocols

For individuals pursuing long-term glutathione optimization, subcutaneous injection may represent the most practical injectable route. It eliminates the need for clinic visits, avoids the spike-and-crash pharmacokinetics of IV delivery, and provides a sustained-release depot that extends the availability of GSH and its precursor amino acids for intracellular resynthesis. The trade-off is lower peak concentrations — but for chronic maintenance (as opposed to acute rescue), that may actually be a feature, not a limitation. The lower peak also reduces the theoretical risk of reductive stress associated with supraphysiological IV bolus concentrations.

Clinical Evidence

Parkinson’s Disease: Two clinical studies on IV glutathione in Parkinson’s disease patients demonstrated significant improvements in motor symptoms after daily IV GSH administered for 30 days. However, both studies found that clinical improvements returned to baseline within approximately two months of stopping treatment, highlighting the transient nature of the benefit.

Oxidative Stress Protection: A clinical comparison of IV glutathione vs. oral NAC for preventing oxidative stress after coronary angiography (a procedure that induces acute oxidative damage) found that IV GSH successfully prevented the rise in oxidative stress markers, while oral NAC had no effect in this acute setting. This underscores that for acute, high-demand oxidative stress situations, injectable glutathione has a clear advantage.

Liver Disease: A study by Dentico et al. (1995) evaluated 30 days of high-dose IV or IM glutathione in patients with chronic fatty liver disease. Significant reductions in liver enzymes (transaminases and GGT) were observed, with some patients maintaining improvements for months after treatment cessation.

The Reductive Stress Concern

A 2025 analysis published in Biomedicine & Pharmacotherapy raised an important caution: IV glutathione produces non-physiological plasma concentrations that may paradoxically cause “reductive stress.” Just as oxidative stress damages cells through excess reactive oxygen species, reductive stress can impair mitochondrial signaling and immune function by disrupting the redox balance in the opposite direction. The study’s authors cautioned that transient symptom relief with high-dose IV antioxidants may reflect metabolic modulation rather than sustainable therapeutic benefit.

Practical Considerations by Route

•       IV dosing: 600–2,000 mg per session, 1–3 times per week; clinical setting required

•       IM dosing: 200–1,000 mg per session, 1–3 times per week; clinical or supervised setting

•       SubQ dosing: 100–500 mg per injection, every 1–3 days; self-administered at home

•       IV cost: $150–$400+ per session; IM cost: $50–$150 per session; SubQ cost: $30–$100+ per month (compounded vials)

•       IV plasma half-life: ~14 minutes; IM peak at ~5 hours; SubQ provides gradual, sustained absorption

•       SubQ requires rotation of injection sites (abdomen, thigh, upper arm) to avoid local irritation

•       All injectable routes: No significant adverse effects reported at standard doses; rare injection site reactions possible

•       FDA safety note: Use only properly compounded, sterile injectable glutathione from licensed compounding pharmacies

The IV Glutathione Paradox

IV glutathione delivers the highest immediate plasma concentrations of any strategy, but the ~14-minute half-life means most of the administered GSH is cleared from circulation within an hour. The body breaks it down into amino acid components that cells can use to resynthesize glutathione internally. This raises a fundamental question: are you paying premium prices for an IV amino acid delivery system that oral NAC or GlyNAC could approximate at a fraction of the cost?

The Aging Edge

Head-to-Head Comparison and the GlyNAC Wild Card

Parameter	Oral NAC	Oral GSH (Liposomal)	Injectable GSH (IV)	Injectable GSH (SubQ)
Bioavailability	6–10% (NAC); effective cysteine delivery	Liposomal: mod-high; Standard: low	~100% immediate plasma delivery	High; slower absorption via depot effect
Onset of Effect	Days to weeks for GSH elevation	1–2 weeks (liposomal)	Immediate spike; ~14 min half-life	Gradual; sustained release over hours
Duration	Sustained with daily use	Sustained with daily use	Transient; requires repeat sessions	Extended depot; more sustained than IV
Mechanism	Indirect: cysteine for endogenous GSH synthesis	Direct: preformed GSH (formulation-dependent)	Direct: immediate plasma GSH flood	Direct: slow-release depot into circulation
Clinical Evidence	Extensive; FDA-approved uses	Moderate; growing liposomal data	Limited; Parkinson’s and acute settings	Minimal published PK data on GSH specifically
Immune Function	Supports via GSH restoration	NK cell activity up 400%	Not well studied	Not well studied
Cost per Month	$3–12	$30–120	$400–1,200+	$30–100 (compounded vials)
Convenience	Daily oral capsule	Daily oral liquid/capsule	Clinical visits 1–3x/week	Self-inject at home every 1–3 days
Self-Regulation	Yes — cells synthesize to demand	Partial	No — bypasses regulation	Partial — lower peak than IV
Reductive Stress Risk	Minimal	Minimal	Possible at high bolus doses	Lower — gradual absorption
Best For	Long-term daily maintenance	Moderate depletion; immune support	Acute crises; severe depletion	Long-term injectable maintenance

The GlyNAC Advantage: The “Power of 3”

Perhaps the most compelling development in glutathione restoration science comes not from any single supplement, but from a combination strategy: GlyNAC — glycine plus N-acetylcysteine. Pioneered by Dr. Rajagopal Sekhar and colleagues at Baylor College of Medicine, this approach addresses a critical gap in standard NAC supplementation.

The rationale is elegant: glutathione synthesis requires three amino acids, and aging depletes not just cysteine (which NAC provides) but also glycine. By supplementing both precursors together, GlyNAC provides the complete substrate package your cells need to manufacture glutathione in physiologically appropriate amounts.

The clinical results have been remarkable. In a randomized clinical trial of older adults (ages 70–80), 24 weeks of GlyNAC supplementation corrected glutathione deficiency, reduced oxidative stress, restored mitochondrial function, lowered inflammation, improved insulin resistance, enhanced endothelial function, reduced genomic damage, and improved muscle strength, gait speed, exercise capacity, and cognitive function. Glutathione levels improved by approximately 200%, inflammatory markers IL-6 dropped by 78% and TNF-α by 57%, and mitochondrial ATP production increased by 83%.

Critically, Dr. Sekhar’s group attributes these sweeping improvements to the combined effects of all three components — glycine, cysteine (from NAC), and the resulting glutathione — not glutathione alone. They call this the “Power of 3.”

One important caveat: benefits declined within 12 weeks of stopping supplementation, indicating that GlyNAC must be taken continuously for sustained effect.

Why GlyNAC May Outperform All Three Individual Strategies

GlyNAC allows your cells to produce exactly the right amount of glutathione based on real-time demand. Unlike IV glutathione (which floods the system with supraphysiological concentrations and is cleared within minutes) or oral GSH (which depends on formulation-dependent absorption), GlyNAC works with your body’s own synthetic machinery. The result is balanced, sustained, intracellular glutathione restoration — which is where GSH actually does its work.

The Bio Precision Aging Protocol

A Tiered Approach Based on Your Goals and Status

Tier 1: Foundational Daily Support (Most People)

Primary: GlyNAC — NAC 600–1,200 mg + Glycine 1–3 g daily. This provides both rate-limiting precursors and allows physiological glutathione synthesis. The most cost-effective strategy with the broadest evidence base for anti-aging benefits.

Alternative: NAC alone — 600–1,200 mg daily if glycine is not available or if budget is constrained. Still effective for cysteine delivery and GSH support, though potentially less comprehensive in older adults.

Tier 2: Enhanced Support (Elevated Oxidative Stress or Immune Concerns)

Add: Liposomal Glutathione — 500–1,000 mg daily as a complement to Tier 1. This provides both precursor support (GlyNAC) and direct GSH supplementation (liposomal) for a dual-pathway approach. Particularly valuable for individuals with documented immune deficits, chronic infections, or high toxic burden.

Tier 3: Injectable Support (Medical Supervision Required)

Option A — Subcutaneous Glutathione (Long-Term Injectable Maintenance): 100–500 mg per injection, self-administered every 1–3 days at home. This is the most practical injectable route for individuals who want sustained direct GSH delivery without the logistical burden and cost of clinic visits. The subcutaneous depot effect provides gradual, extended absorption that avoids the spike-and-crash profile of IV, while still bypassing GI degradation entirely. Requires an initial prescription and compounded formulation from a licensed compounding pharmacy. Ideal for individuals who have established a Tier 1/2 foundation and want to add direct GSH delivery, or for those who find oral formulations insufficient based on measured biomarkers.

Option B — IV Glutathione (Acute or Clinical Intervention): 600–2,000 mg per session, administered under medical supervision in a clinical setting. Reserved for acute oxidative stress events (e.g., post-surgical recovery, acute toxic exposure, neurodegenerative support), severe measured depletion, or as a short-term boost while establishing Tier 1/2 protocols. Not recommended as a standalone long-term strategy due to transient pharmacokinetics (~14-minute half-life) and high cost.

Option C — IM Glutathione: 200–1,000 mg per session, 1–3 times weekly. A middle ground between IV and SubQ, with peak absorption at approximately 5 hours. Useful for individuals who want injectable glutathione but prefer less frequent dosing than SubQ. Requires clinical or supervised administration.

The Bio Precision Aging Position: The evidence strongly supports GlyNAC as the foundation of any glutathione restoration protocol for aging adults. It addresses the root cause — precursor deficiency — rather than attempting to bypass the body’s own synthesis. Layer liposomal GSH for enhanced direct support when indicated. For those who want injectable delivery, subcutaneous glutathione offers the best balance of sustained pharmacokinetics, home convenience, and cost-effectiveness for long-term use. Reserve IV glutathione for acute clinical situations where immediate maximum elevation is needed. Average is not the target. Build the foundation first, then optimize.

To Be Precise

Summary and Actionable Takeaways

Glutathione is the body’s most critical endogenous antioxidant, and its decline with aging triggers a cascade of dysfunction spanning mitochondrial health, immune function, inflammation, cognitive performance, and metabolic resilience. Restoring glutathione is not optional for anyone serious about longevity — it is foundational.

The evidence-based hierarchy:

1. GlyNAC (Glycine + NAC) is the strongest all-around strategy. It provides both rate-limiting precursors, supports self-regulated intracellular GSH production, and has the most impressive clinical outcomes across multiple aging hallmarks — oxidative stress, mitochondrial function, inflammation, cognition, strength, and metabolic health.

2. Liposomal Glutathione is a powerful adjunct. It delivers preformed GSH with meaningfully improved absorption compared to standard oral glutathione. The immune function data — particularly the dramatic increases in NK cell activity — make it especially relevant for immune-compromised individuals or those with high oxidative burden.

3. Injectable Glutathione bypasses GI degradation entirely, but the three routes serve different purposes. IV delivers the highest immediate plasma levels but with a ~14-minute half-life, making it best suited for acute clinical situations. Intramuscular injection offers a moderate depot effect with peak absorption around 5 hours. Subcutaneous injection provides the most sustained absorption profile of any injectable route, with the major advantage of home self-administration — making it the most practical injectable option for long-term longevity protocols. For individuals who want the directness of injectable delivery without the logistical burden and cost of IV clinic visits, SubQ glutathione is the standout choice.

4. Standard oral glutathione (non-liposomal) has the weakest acute bioavailability data, though longer-duration studies suggest some benefit over months. If this is your only option, use it — but recognize that formulation upgrades (liposomal, sublingual) or precursor strategies (NAC, GlyNAC) are likely to deliver superior results.

Bottom line: Start with GlyNAC. If you want to accelerate or layer additional direct GSH support, add a quality liposomal glutathione. If you want injectable delivery for sustained direct GSH support, subcutaneous glutathione offers the best combination of pharmacokinetics, convenience, and cost for long-term use. Reserve IV glutathione for acute clinical situations under medical guidance. This is not an either/or decision — it is a precision stack, calibrated to your individual status, goals, and biology.

Prioritize the strategy that works with your biology, not the one that tries to bypass it.

References

1. Aebi S, Assereto R, Lauterburg BH. High-dose intravenous glutathione in man: pharmacokinetics and effects on cyst(e)ine in plasma and urine. Eur J Clin Invest. 1991;21(1):103–110.

2. Richie JP Jr, Nichenametla S, Neidig W, et al. Randomized controlled trial of oral glutathione supplementation on body stores of glutathione. Eur J Nutr. 2015;54(2):251–263.

3. Sinha R, Sinha I, Calcagnotto A, et al. Oral supplementation with liposomal glutathione elevates body stores of glutathione and markers of immune function. Eur J Clin Nutr. 2018;72(1):105–111.

4. Schmitt B, Vicenzi M, Garrel C, Denis FM. Effects of N-acetylcysteine, oral glutathione (GSH) and a novel sublingual form of GSH on oxidative stress markers: a comparative crossover study. Redox Biol. 2015;6:198–205.

5. Kumar P, Liu C, Suliburk J, et al. Supplementing glycine and N-acetylcysteine (GlyNAC) in older adults improves glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, physical function, and aging hallmarks: a randomized clinical trial. J Gerontol A Biol Sci Med Sci. 2023;78(1):75–89.

6. Kumar P, Liu C, Hsu JW, et al. Glycine and N-acetylcysteine (GlyNAC) supplementation in older adults improves glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, insulin resistance, endothelial dysfunction, genotoxicity, muscle strength, and cognition: results of a pilot clinical trial. Clin Transl Med. 2021;11(3):e372.

7. Dentico P, Volpe A, Buongiorno R, et al. Glutathione in the treatment of chronic fatty liver diseases. Recenti Prog Med. 1995;86(7–8):290–293.

8. Sechi G, Deledda MG, Bua G, et al. Reduced intravenous glutathione in the treatment of early Parkinson’s disease. Prog Neuropsychopharmacol Biol Psychiatry. 1996;20(7):1159–1170.

9. Hauser RA, Lyons KE, McClain T, Carter S, Perlmutter D. Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson’s disease. Mov Disord. 2009;24(7):979–983.

10. Smeyne M, Smeyne RJ. Glutathione metabolism and Parkinson’s disease. Free Radic Biol Med. 2013;62:13–25.

11. Witschi A, Reddy S, Stofer B, Lauterburg BH. The systemic availability of oral glutathione. Eur J Clin Pharmacol. 1992;43(6):667–669.

12. Allen J, Bradley RD. Effects of oral glutathione supplementation on systemic oxidative stress biomarkers in human volunteers. J Altern Complement Med. 2011;17(9):827–833.

13. Pizzorno J. Glutathione! Integr Med (Encinitas). 2014;13(1):8–12.

14. Forman HJ, Zhang H, Rinna A. Glutathione: overview of its protective roles, measurement, and biosynthesis. Mol Aspects Med. 2009;30(1–2):1–12.

Disclaimer: This article is for educational and informational purposes only and does not constitute medical advice. Glutathione supplementation strategies, including injectable formulations, should be discussed with a qualified healthcare provider. Individual results may vary based on genetics, health status, and concurrent medications. Always consult your physician before beginning any new supplement or injectable protocol.

© Bio Precision Aging  |  bioprecisionaging.com  |  Where Average Is Not the Target